Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database
- PMID: 27059708
- PMCID: PMC4840034
- DOI: 10.1002/clc.22503
Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database
Abstract
We sought to determine use of any and at least moderate-intensity statin therapy in a national sample of patients with diabetes mellitus (DM), with the hypothesis that nationwide frequency and facility-level variation in statin therapy are suboptimal. We sampled patients with DM age 40 to 75 years receiving primary care between October 1, 2012, and September 30, 2013, at 130 parent facilities and associated community-based outpatient clinics in the Veterans Affairs Health Care System. We examined frequency and facility-level variation in use of any or at least moderate-intensity statin therapy (mean daily dose associated with ≥30% low-density lipoprotein cholesterol lowering). In 911 444 patients with DM, 68.3% and 58.4% were receiving any and moderate- to high-intensity statin therapy, respectively. Patients receiving statin had higher burden of cardiovascular disease, were more likely to be on nonstatin lipid-lowering therapy and to receive care at a teaching facility, and had more frequent primary-care visits. Median facility-level uses of any and at least moderate-intensity statin therapy were 68.7% (interquartile range, 65.9%-70.8%) and 58.6% (interquartile range, 55.8%-61.4%), respectively. After adjusting for several patient-related and some facility-related characteristics, the median rate ratios for any and moderate- to high-intensity statin therapy were 1.20 (95% confidence interval: 1.18-1.22) and 1.29 (95% confidence interval: 1.24-1.33) respectively, indicating 20% to 29% variation in statin use between 2 identical patients receiving care at 2 random facilities. Statin use was suboptimal in a national sample of patients with DM with modest facility-level variation, likely indicating differences in statin-prescribing patterns.
© 2016 Wiley Periodicals, Inc.
Figures


Similar articles
-
Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.Circ Cardiovasc Qual Outcomes. 2018 May;11(5):e004652. doi: 10.1161/CIRCOUTCOMES.118.004652. Circ Cardiovasc Qual Outcomes. 2018. PMID: 29748356 Free PMC article.
-
Temporal Trends of High-Intensity Statin Therapy Among Veterans Treated With Percutaneous Coronary Intervention.J Am Heart Assoc. 2018 Mar 4;7(5):e007370. doi: 10.1161/JAHA.117.007370. J Am Heart Assoc. 2018. PMID: 29503265 Free PMC article.
-
Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs.Vasc Med. 2018 Jun;23(3):232-240. doi: 10.1177/1358863X18758914. Epub 2018 Mar 30. Vasc Med. 2018. PMID: 29600737
-
Sex Differences in the Use of Statins in Community Practice.Circ Cardiovasc Qual Outcomes. 2019 Aug;12(8):e005562. doi: 10.1161/CIRCOUTCOMES.118.005562. Epub 2019 Aug 16. Circ Cardiovasc Qual Outcomes. 2019. PMID: 31416347 Free PMC article.
-
Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context.Prog Cardiovasc Dis. 2021 Sep-Oct;68:2-6. doi: 10.1016/j.pcad.2021.08.001. Epub 2021 Aug 8. Prog Cardiovasc Dis. 2021. PMID: 34371083 Review.
Cited by
-
Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.BMC Health Serv Res. 2018 Nov 28;18(1):900. doi: 10.1186/s12913-018-3707-4. BMC Health Serv Res. 2018. PMID: 30486824 Free PMC article.
-
Lipid-Lowering Prescription Patterns in Patients With Diabetes Mellitus or Cardiovascular Disease.Am J Cardiol. 2019 Oct 1;124(7):995-1001. doi: 10.1016/j.amjcard.2019.07.002. Epub 2019 Jul 15. Am J Cardiol. 2019. PMID: 31362878 Free PMC article.
-
Association of country economy and socioeconomic factors on risk factor control for primary prevention of cardiovascular disease in patients with diabetes mellitus: Insights from the DISCOVER study.Indian Heart J. 2022 Sep-Oct;74(5):398-405. doi: 10.1016/j.ihj.2022.07.008. Epub 2022 Aug 2. Indian Heart J. 2022. PMID: 35926587 Free PMC article.
-
Prescribing patterns of statins and associated factors among type 2 diabetes mellitus patients in Africa: A systematic review and meta-analysis.Metabol Open. 2024 Jun 20;23:100297. doi: 10.1016/j.metop.2024.100297. eCollection 2024 Sep. Metabol Open. 2024. PMID: 39006881 Free PMC article.
-
Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD.Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1842-1850. doi: 10.2215/CJN.03830318. Epub 2018 Nov 29. Clin J Am Soc Nephrol. 2018. PMID: 30498000 Free PMC article.
References
-
- Kearney PM, Blackwell L, Collins R, et al; Cholesterol Treatment Trialists' Collaborators . Efficacy of cholesterol‐lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta‐analysis. Lancet. 2008;371:117–125. - PubMed
-
- American Diabetes Association . Cardiovascular disease and risk management. Diabetes Care. 2015;38(suppl 1):S49–S57. - PubMed
-
- Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014;129(25 suppl 2):S46–S48]. Circulation. 2014;129(25 suppl 2):S1–S45. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical